Semaglutide CAS:910463-68-2

Views : 91
Author :
Update time : 2023-09-08 15:20:20
Somalutide(CAS No.:910463-68-2)generally refers to somalutide injection, simethicone generally refers to simethicone injection, the difference between the two drugs, including different principles, different treatment diseases, different contraindications, etc., can be analysed on a case-by-case basis.
1. The principle is different: somaglutide injection is through the activation of glucagon-like peptide-1 receptor, improve the efficiency of intestinal insulin function, to achieve the purpose of lowering sugar. Somaglutide injection is to promote insulin secretion and inhibit glucagon secretion to achieve the purpose of lowering blood sugar.
2. The treatment of different diseases: somatostatin injection is mainly used for the treatment of type 2 diabetes mellitus. Somaglutide injection, can reduce the risk of adverse cardiovascular events in adult patients with type 2 diabetes mellitus accompanied by cardiovascular disease.
3. Different contraindications: somatostatin injection is not recommended for patients with multiple endocrine adenoma syndrome. Simeglutide injection is generally not recommended for patients with medullary thyroid carcinoma and endocrine tumours.
In addition to this, there are also different applicable populations, different side effects of the drug, and different ingredients of the drug. It is necessary to follow the doctor's instructions when using the drug, and not to use the drug blindly by oneself, so as not to induce adverse drug reactions.